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INTRODUCTION
Angiogenesis is the process by which new blood vessels 
develop from existing microvasculature in a variety of 
physiologic states. Angiogenesis is essential for solid 
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Objective: The purpose of this research was to investigate the anti-angiogenic inhibitory effect of KR-31831, a newly 
developed anti-angiogenic agent, on an in vivo human ovarian carcinoma model using dynamic contrast-enhanced (DCE) MRI. 
Materials and Methods: Xenografted ovarian tumors were established by subcutaneous injection of SKOV3 cells into mice. 
The mice were treated daily with KR-31831 at 50 mg/kg for 21 days. Tumor tissues were excised corresponding to the DCE-
MRI sections for evaluation of MVD with CD31 immunohistochemistry. All in vivo MRIs were performed on a 7.0 Tesla micro-
MRI System. DCE-MRI was acquired prior to initiating treatment with KR-31831 and again on days 3 and 21 after treatment. 
The permeability parameters (K
trans, ve, and vp) were estimated using a pharmacokinetic model.
Results: Qualitatively, the K
trans parametric mapping showed different changes before and after treatment with KR-31831 in 
the treatment group. For quantification of this change, the median of K
trans values were compared before and after 
treatments in the control and KR-31831-treated groups. A non-parametric statistical test (Wilcoxon signed-rank test) 
showed decreasing K
trans values on day 21 compared to days 0 and 3 in the KR-31831-treated group (p < 0.05), whereas 
there was no significant difference in the control group (p = 0.84).
Conclusion: Our results suggest that DCE-MRI can be a useful tool by which to evaluate the anti-angiogenic effect of KR-
31831 on a xenografted human ovarian carcinoma model.
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tumor growth, invasion and metastatic pathway. Without 
angiogenesis, tumor growth cannot proceed beyond 1-2 
mm
2 because tumor growth is severely limited by oxygen, 
the nutrient supply, and removal of waste products into 
the surrounding medium (1-3). For many tumors, vascular 
density provides a prognostic indicator of metastatic 
potential, with highly vascular primary tumors having 
a higher incidence of metastasis than poorly vascular 
tumors. Tumor angiogenesis is a promising targeting 
for development of novel anti-cancer therapies because 
endothelial cells are thought to be genetically stable 
compared with tumor cells. 
Tumor angiogenesis is regulated by the production of 
angiogenic stimulators and inhibitors. In recent years, it 
has been well-established that tyrosine kinase receptors Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 603
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of vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), and platelet-derived growth factor 
(PDGF) are strongly implicated in angiogenesis associated 
with solid tumors (4-8). One of the most specific and 
critical regulators of angiogenesis is VEGF, which regulates 
endothelial proliferation, permeability, and survival. VEGF 
is a mitogen for vascular endothelial cells derived from 
arteries, veins, and lymphatics (6, 9). VEGF has been shown 
to play a coordinated role in endothelial cell proliferation 
and assembly of the vessel wall in a variety of normal and 
abnormal circumstances by activating the mitogen-activated 
protein kinase/extracellular signal-regulated kinase and 
phosphatidylinositol 3'-kinase/AKT pathways, and VEGF is 
also a survival factor for normal and tumor endothelium 
(5, 10). The VEGF signaling pathway is activated by ligand-
induced phosphorylation of the VEGF receptors (VEGFRs). 
The blocking of VEGFR phosphorylation by a kinase inhibitor 
is expected to disrupt VEGF signaling pathways resulting in 
changes in tumor vascular characteristics and growth (10-
13). 
(2R,3R,4S)-6-amino-4-[n-(4-chlorophenyl)-N-(1H-
imidazon-2ylmethyl)amino]-3-hydroxyl-2-methyl-
2dimenhoxymethyl-3,4-dihydro-2H-1-benzopran (KR-31831) 
is a newly developed small molecular weight drug used as an 
anti-angiogenic inhibitor in our co-worker group. KR-31831 
has been reported to suppress endothelial cell proliferation, 
tube formation, invasion, and migration in vitro (14, 15, 
17). Also, KR-31831 inhibits vessel formation in the mouse 
Matrigel plug assay in vivo (15-17). Although the specific 
mechanisms underlying the anti-angiogenic effects of this 
new synthetic agent are not fully understood, the inhibitory 
mechanism of KR-31831 on tumor angiogenesis, especially 
on the VEGF-signaling pathway in human umbilical vein 
endothelial cells (HUVECs), has been thoroughly studied. 
KR-31831 down-regulates VEGF-induced tumor formation 
and proliferation of HUVECs by inhibiting intracellular 
Ca
2+ release and phosphorylation of extracellular regulated 
kinase 1/2 (Erk1/2). Moreover, the expression of VEGF 
receptor 2 (VEGFR2 [also known as Flk-1 or KDR]) was also 
reduced by the treatment of KR-31831 (16, 17). 
Technical advances in magnetic resonance imaging (MRI) 
have improved the non-invasive measurement of functional 
information about tumors for the diagnosis and assessment 
of treatment response (18, 19). Dynamic contrast-
enhanced (DCE) MRI has the ability to non-invasively 
detect morphologic and functional characteristics of tumor 
vasculature, including the anti-angiogenic response of 
tumors by the differential distribution of contrast agent 
in tissues (20). By quantification of tumor perfusion and 
capillary permeability, this technique allows for assessment 
of anti-angiogenic treatment response more readily than 
indirect and delayed assessment of tumor size. 
In the current study we tested the in vivo anti-angiogenic 
efficacy of the newly developed angiogenesis inhibitor, KR-
31831, using quantification of DCE-MRI in mice bearing 
SKOV3 tumor.
MATERIALS AND METHODS
Cell Culture
The human ovarian carcinoma cell line, SKOV3, was 
obtained from the American Type Culture Collection 
(Manassas, VA) and cultured in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS) and 
1% ampicillin and streptomycin. Cells were cultured at 
37°C in a humidified incubator containing 5% CO2 and 
routinely passaged twice a week at a split ratio of 1:3. 
All experiments were performed with 70-80% confluent 
cultures. 
 
Subcutaneous Ectopic Xenograft Tumor Model and 
Treatment
The anti-angiogenic efficacy of KR-31831 was tested in 
mice bearing ectopic SKOV3 tumors. Female BALB/c nu/
nu mice (7 weeks old) were purchased from Orient Bio 
(Seoul, South Korea) and housed in specific pathogen-free 
conditions. The mice were cared for in accordance with 
guidelines set forth by the American Association for the 
Accreditation of Laboratory Animal Care (AAALAC), and 
all studies with mice were reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) of 
Samsung Biomedical Research Institute (SBRI). SBRI is an 
Association for Assessment and Accreditation of Laboratory 
Animal Care International-accredited facility and abides by 
the Institute of Laboratory Animal Resources (ILAR) guide. 
Ectopic xenograft tumors were established by subcutaneous 
injection of 2 x 10
6 SKOV3 cells in a total volume of 0.1 
mL of a serum-free medium containing 50% Matrigel (BD 
Bioscience, Erembodegem, Belgium) into the right thigh 
under isoflurane anesthesia. As the tumors became palpable, 
the mice were randomly assigned into treatment and control 
groups (six mice per group). KR-31831 was obtained from 
the Korea Research Institute of Chemical Technology and 
prepared as a suspension in vehicle (10% cremophor [vol/Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 604
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vol] and 10% absolute ethyl alcohol [vol/vol] in normal 
saline) for intraperitoneal injection into xenograft-bearing 
athymic nude mice. KR-31831 therapy was initiated 14 
days after THE cell line injection. In the treated group 
(n = 6), mice were treated daily with KR-31831 (50 mg/
kg). In the control group (n = 6), mice were also treated 
daily with vehicle alone intraperitoneally for 21 days. 
Immediately after DCE-MRI data acquisition, all of the mice 
were maintained under anesthesia using 1.5% isoflurane, 
70% N2O, and 30% O2, and transcardially perfused with 0.9% 
normal saline followed by 10% neutral buffered formalin 
(NBF) solution. For the subsequent histologic analysis, the 
tumor tissue was removed, fixed further in 10% NBF for 24 
hrs, then sliced in accordance with MR images.
MRI Data Acquisition
All data were obtained using a 7.0 Tesla (T) micro-
MRI System (20 cm gradient set, and 72 mm i.d. birdcage 
coil; Bruker-Biospin, Fallanden, Switzerland). Mice were 
anesthetized with 1.5% isoflurane in 70% N2O and 30% 
O2 using an MR-compatible mobile inhalation anesthesia 
system. DCE-MR imaging was performed using a coronal T1-
weighted 3D gradient echo sequence, as follows: FLASH 
sequence; TR = 67 ms; TE = 3 ms; flip angle = 70°; FOV = 
30 x 30 mm; imaging matrix = 128 x 128; slice thickness = 
2.5 mm; temporal resolution = 6 s; and 120 dynamics. For 
T1 mapping, 5 pre-contrast scans were acquired with the 
same post-contrast parameters, but different flip angles (5°, 
15°, 35°, 60°, and 70°). Baseline images were acquired for 
approximately 60 s, followed by an automatic injection over 
4-5 s of 0.1 mmol/kg of Dotarem via the tail vein, followed 
by further acquisitions, up to a total time of 12 min (120 
images).
MRI Data Analysis
The concentration of contrast agent was estimated by 
determination of the difference in longitudinal relaxation 
rates, as follows: C(t) = (1/T1[t] - 1/T1[0])/r1, where T1 
(t) and T1 (0) are the post- and pre-contrast T1 values, 
respectively, and r1 denotes the longitudinal relaxivity 
(2.92 s
-1mM
-1) (20). DCE-MRI data were converted into the 
concentration of the contrast agent using a different flip 
angle method (21). The general equation for SI values at a 
given flip angle is as follows:
where TR is the repetition time, α is the flip angle, and M0 
is the equilibrium longitudinal magnetization. The M0 and T1 
parameter were estimated by a linear least-squares method 
using 5 MR images (5°, 15°, 35°, 60°, and 70°). Following 
the estimation of M0 and T1 (0) values for the pre-contrast 
image, post-contrast T1 value (T1 [t]) can be estimated as a 
function of time from the SI (t) for the post-contrast image 
with an α = 70°. 
We used the extended Kety two-compartment model for 
quantification of tissue concentration (22), as follows:
where Ct is the concentration of the contrast agent in the 
observed tissue, CP is the concentration in blood plasma, 
vp is the fractional blood plasma volume per unit volume of 
tissue, K
trans is the volume transfer constant, and ve is the 
fractional extravascular extracellular space (EES) per unit 
volume of tissue. The homemade software was implemented 
for performance of non-linear fitting of tissue concentration 
curves using the MATLAB lsqnonlin function. 
The arterial input function (AIF) was manually defined 
at baseline for each mouse using Analysis of Functional 
NeuroImages (AFNI [http://afni.nimh.nih.gov/afni/)] 
(23), and used for quantification of DCE-MRI on days 0, 3, 
and 21. With AFNI software, users move the cursor to the 
voxel in a concentration image window; the corresponding 
concentration time curve is then displayed in a time profile 
window. The AIF voxels were manually selected in a voxel-
by-voxel manner by visual inspection of voxel concentration 
profiles in AFNI software. 
Immunohistochemical Analysis for Quantification of 
Microvessel Density
Formalin-fixed, paraffin-embedded tumor tissues 
were serially sliced into 5 µm sections corresponding 
to the magnetic resonance images for quantification of 
microvessel density (MVD) with CD31 staining by the 
immunohistochemical method. After heat-induced antigen 
retrieval for 20 min in citrate buffer (pH 6.0), endogenous 
peroxidase was blocked with 3% hydrogen peroxide in 
phosphate-buffered saline (PBS) for 10 min. Non-specific 
epitopes were blocked with blocking solution (2.5% normal 
SI (α) = 
M0  1 - e -        sin α
1 - cos αe -
- TR
- T1
- TR
- T1
(
(
)
)
Ct (t) = K
trans Cp (t) x exp( -K
trans
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horse serum) for 20 min at room temperature followed by 
incubation with anti-mouse CD31 (1:150; BD-Pharmingen, 
Erembodegem, Belgium) antibody diluted in PBS containing 
1% bovine serum albumin at room temperature for 30 min. 
After washing with PBS, the tissue sections were incubated 
with biotin-conjugated IgG for 30 min, then washed again 
followed by incubation with horseradish peroxidase (HRP)-
conjugated streptavidin for 30 min. The color reaction was 
developed using the chromogen 3,3-diaminobenzidine (DAB) 
for 5 min. After washing, the tissue sections were lightly 
counterstained with Mayer’s hematoxylin before dehydration 
and mounting. MVD was determined by examining the 
viable tumor area without necrosis in 12 mice (control [n 
= 6] and treated [n = 6]), as described previously (24). 
Individual microvessels were counted in 5 random fields 
per individual tumor section at 200X magnification. Brown-
staining endothelial cells that were clearly separate in 
brown appearance were counted as individual vessels. The 
results were expressed as an average of the total number of 
microvessels observed in each individual tumor.
Statistical Analysis
The pharmacokinetic parameters (K
trans, ve, and vp) were 
estimated from DCE-MRI data using the pharmacokinetic 
modeling method before and after treatment with KR-31831 
(3 and 21 days). The median and range of pharmacokinetic 
parameters were examined. The non-parametric statistical 
analysis (Wilcoxon signed-rank test) was performed to test 
significant differences in pharmacokinetic parameters before 
and after treatment with KR-31831 at a p < 0.05. 
RESULTS
The AIF was manually defined by visual inspection of 
concentration profiles before treatment (day 0). Figure 1A 
shows representative images of the AIF near the femoral 
artery, and Figure 1B demonstrates the concentration profile 
of the AIF, which was averaged across the manually-defined 
AIF voxels in Figure 1A. 
For quantification of DCE-MRI parameters, the regions 
of interest (ROI) were manually-defined on anatomic T2-
weighted images, as shown in Figure 2A. A non-linear 
fitting method was used to fit the observed concentration 
profiles of tumor tissues (Ct) and arterial vessels (Cp) 
into the pharmacokinetic model (the extended Kety two-
compartment model). The fitted concentration of tumor 
tissues is shown in Figure 2B; the results showed that the 
estimated K
trans parameter was 0.145, the ve was 0.868, and 
the vp was 0.0441.
Figure 3 shows the representative pharmacokinetic 
parametric mapping obtained from the control mice (Fig. 
3A) and the KR-31831-treated mice (Fig. 3B) on days 0, 3, 
and 21 after treatment. To quantify changes in parameters 
between before and after treatment, the medians of 
the pharmacokinetic parameters (K
trans, ve, and vp) were 
extracted from the tumor region for each subject, and 
these parameters were compared on days 0, 3, and 21 after 
treatment for each group (Table 1). Figure 4 demonstrated 
that there were significant decreasing K
trans values on day 21 
compared to days 0 and 3 in the KR-31831-treated group 
(p < 0.05), whereas there was no significant difference in 
the control group (p = 0.84) using the Wilcoxon signed-
rank test. There was no significant difference between the 
Fig. 1. Determination of arterial input function. 
A. Manually-defined arterial input function voxels by visual inspection of concentration time curves are shown in red. B. Representative 
concentration profile of arterial input function defined in A. 
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control and KR-31831 groups with respect to K
trans values 
at baseline (day 0); other parameters (ve, and vp) were not 
significantly different in the KR-31831-treated and control 
groups. 
Immunohistochemical analysis for MVD performed on 
control and KR-31831-treated tumor tissues 21 days after 
treatment. As shown in Figure 5, tumor microvessels 
immunohistochemically analyzed with CD31 antibody 
reactivity in vascular tumor areas without necrosis in 
corresponding MRI sections were also significantly reduced 
in KR-31831-treated tumors compared to controls. 
Quantitative analysis of MVD was performed by examining 
individual microvessels in five random fields per tumor 
section under high-field magnification. The MVD was 18.6 
± 5.2 in control mice, while the MVD was 14.9 ± 4.0 and 
significantly reduced by approximately 20% in KR-31831-
KR 31831
A
B
Fig. 3. Pharmacokinetic parametric mapping in control and KR-31831-treated mice on days 1, 3, and 21. 
A. K
trans map for control mice. B. K
trans map for KR-31831-treated mice. Color schema ranges from 0 (blue) to 0.02 (red). 
Control
0 Day
0 Day
3 Day
3 Day
21 Day
21 Day
Fig. 2. Non-linear fitting using pharmacokinetic modeling method.
A. Manually-defined tumor region is shown in blue. B. Representative concentration profile of tumor region (blue circle), and fitted data (red dot-
line) using non-linear fitting method.
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treated mice (p < 0.05) (Fig. 5C).
DISCUSSION
Angiogenesis, the recruitment of new blood vessels, is 
the process by which new blood vessels grow in a variety of 
physiologic and pathophysiologic states. However, it is still 
a matter of debate whether or not MVD is a good indicator 
of the therapeutic efficacy of anti-angiogenic drugs.
Targeted therapy for angiogenesis represents a promising 
strategy for the development of anti-cancer drugs as several 
pre-clinical studies have shown that angiogenesis is a key 
pathway for tumor growth, invasion, and metastasis (3, 
6, 10, 25). Furthermore, clinical trials in cancer patients 
are ongoing with several VEGF inhibitors, including a 
humanized monoclonal antibody (26) and various small 
molecules inhibiting signal transduction (9, 27, 28).
A number of endogenous proteins that act as positive 
regulators or activators of tumor angiogenesis have been 
identified, including VEGF, basic fibroblast growth factor 
(bFGF), tumor necrosis factor alpha (TNF-α), angiopoietin-1 
and -2, interleukin (IL)-8, and platelet-derived growth 
factor beta (PDGF-ß) (10, 27). One of the more potent 
endothelial mitogens is VEGF, also known as vascular 
permeability factor (VPF) because it was initially recognized 
for its ability to increase microvascular permeability. 
VEGF is widely distributed and has been shown to play a 
coordinated role on the vascular endothelium, including 
endothelial mitogenesis, permeability, vascular tone, the 
production of vasoactive molecules, and the stimulation of 
monocyte chemotaxis (6, 13, 26). There are five members 
of the VEGF family in addition to four members of the 
angiopoietin family and at least one member of the ephrin 
family of regulators; the regulators must all work in a 
complementary and coordinated manner to form functional 
vessels (5, 25). A large number of anti-angiogenic drugs 
have been targeted against the angiogenic cytokine, 
VEGF. This cytokine is a principal mediator of vascular 
permeability, which has been measured by DCE-MRI and 
used as a pharmacodynamic end point for the development 
of these new compounds. Therefore, we designed this study 
to evaluate the anti-angiogenic efficacy of KR-31831 using 
DCE-MRI. 
KR-31831 is a 4-(N-imidazol-2-ylmethyl) aminobenzopyran 
Table 1. Descriptive Statistics of K
trans, ve, and vp Values on Days 0, 3, or 21 after Treatment in Each Group
0 Day 3 Days 21 Days
Control KR-31831 Control KR-31831 Control KR-31831
K
trans 0.008  
(0.0061-0.0093)
0.0099  
( 0.0062-0.0194 )
0.0099 
(0.0044-0.0137)
0.0108  
(0.0063-0.0146)
0.0043  
(0.0031-0.0072)
0.0057  
(0.0045-0.0069)
ve
0.3137 
(0.1959-0.5958)
0.3802 
(0.3020-0.5559)
0.4022 
(0.2297-0.6021)
0.432 
(0.2788-0.6089)
0.3077  
(0.1930-0.7080)
0.3296 
(0.2908-0.3806)
vp
0.015  
(0.0028-0.0314)
0.0207  
(0.0114-0.0527)
0.0286  
(0.0117-0.0444)
0.0319  
(0.0089-0.0582)
0.0246  
(0.0071-0.0567)
0.0185  
(0.0056-0.0374)
Note.— All data are presented as median and range (minimum and maximum).
*
*
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Fig. 4. Wilcoxon signed-rank test (K
trans parameter) before and after treatments in control and KR-31831-treated groups. *p < 0.05Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 608
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analogue originally designed for the treatment of ischemic 
diseases, such as myocardial infarction and stroke, by a 
group of our co-workers (16, 17). Benzopran is one of 
the most frequently used backbones of synthetic drugs, 
including anti-oxidants, anti-hypertensives, and therapeutic 
agents for ischemia-related diseases. A variety of amines 
were introduced at the 4-position of benzopyran for the 
identification of adenosine triphosphate (ATP)-sensitive 
potassium channel (KATP) openers targeting ischemic disease, 
such as myocardial infarction and stroke. Previously, the 
group of co-workers demonstrated the ability of KR-31831 
to inhibit VEGF-induced vascular permeability in in vitro and 
in vivo experiments (14, 15). Specifically, KR-31831 was 
shown to exert anti-angiogenic activities as measured by 
the inhibitory effect on HUVEC tube formation. Additionally, 
KR-31831 also showed inhibitory effects on VEGF-activated 
cell proliferation, migration, and invasion.
Dynamic contrast-enhanced MRI involves the acquisition 
of sequential images during the passage of a contrast 
agent through a particular tissue of interest. Analysis of 
DCE-MR images allows the generation of signal intensity 
versus time graphs. There have been two kinds of methods 
for quantification of DCE-MRI. Semi-quantitative analysis 
is based on the characterization of shape of time-to-
signal curves which enable measurement of maximum 
enhancement, peak enhancement, before arrival time, 
and wash-in and -out slopes (29-31). However, these 
parameters are not associated with physiologic parameters, 
and are also not comparable among different MRI scanners. 
Alternative methods have been developed based on the 
pharmacokinetic model to estimate physiologic parameters, 
which have been proposed by Tofts and Kermode (32), Brix 
et al. (33), and Larsson et al. (34). These different models 
have been standardized in terms of quantities and symbols 
based on the assumption that tissue is composed of the 
extravascular extracellular space (EES) and the plasma 
space (vp), and the transport between EES and vp (volume 
transfer constant, K
trans) (22). In the current study, we 
Fig. 5. Representative immunohistochemical analysis of microvessel density of xenografted SKOV3 tumor tissues obtained from 
control (A) and KR-31831-treated groups (B) in accordance with dynamic contrast-enhanced MRI sections at end time point of 
treatment. Vessels show dark brown color. Scale bar, 100 µm. Microvessel density was quantified and averaged in five random fields without 
necrosis per tumor at 200X magnification. Note microvessel density/field (C) was significantly reduced in tumor tissue from KR-31831 treatment 
group (14.9 ± 4.0) compared with control group (18.6 ± 5.2). p < 0.05. Error bars, SD.
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used the generalized Tofts model (extended Kety model) 
to quantify pharmacokinetic parameters form murine data, 
and our results showed the feasibility of DCE-MRI tools 
for evaluation of anti-angiogenic efficacy of the newly 
developed angiogenesis inhibitor, KR-31831. 
In conclusion, the effect of KR-31831 on xenografted 
human ovarian tumor vasculature has been studied using 
DEC-MRI and a CD31 immunohistochemical method. As 
expected, a significant reduction in MVD was in agreement 
with the DCE-MRI finding of a decrease in fractional plasma 
volume and transendothelial permeability, thus providing 
a very robust demonstration of KR-31831 efficacy. Our 
results indicate that KR-31831 may offer opportunities 
for novel therapeutic strategies in ovarian carcinoma and 
DCE-MRI may be a useful tool to evaluate the effect of 
newly developed candidate drugs (such as KR-31831) on 
angiogenesis.
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